Prescription of opioids for breathlessness in end-stage COPD: A national population-based study

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2651-2657

  Ahmadi, Zainab ^a,b   Bernelid, Eva ^b   Currow, David C ^c   Ekström, Magnus ^a,b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b BLEKINGE HOSPITAL   (Sweden)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Breathlessness; COPD; LTOT; Opioids; Prescriptions; Symptoms

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; FENTANYL; MORPHINE; OPIATE DERIVATIVE; OXYCODONE; OXYGEN; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DRUG INDICATION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PAIN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; SWEDEN; CLINICAL PRACTICE; DRUG UTILIZATION REVIEW; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTER; TIME FACTOR; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DYSPNEA; FEMALE; GUIDELINE ADHERENCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85015994874     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S112484     Document Type: Article

References (31)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095–2128.
2. Walke LM, Byers AL, Tinetti ME, Dubin JA, McCorkle R, Fried TR. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. Arch Intern Med. 2007;167(22):2503–2508.
3. Johnson MJ, Bowden JA, Abernethy AP, Currow DC. To what causes do people attribute their chronic breathlessness? A population survey. J Palliat Med. 2012;15(7):744–750.
4. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540.
5. Moens K, Higginson IJ, Harding R. EURO IMPACT. Are There differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manage. 2014;48(4):660–677.
6. Ahmadi Z, Lundström S, Janson C, et al. End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. Eur Respir J. 2015;46(4):1190–1193.
7. Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 2005;19(6):485–491.
8. Gulbas G, Gunen H, In E, Kilic T. Long-term follow-up of chronic obstructive pulmonary disease patients on long-term oxygen treatment. Int J Clin Pract. 2012;66(2):152–157.
9. Law S, Boyd S, Macdonald J, Raeside D, Anderson D. Predictors of survival in patients with chronic obstructive pulmonary disease receiving long-term oxygen therapy. BMJ Support Palliat Care. 2014. doi:10.1136/bmjspcare-2012-000432.
10. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.
11. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4): 435–452.
12. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–944.
13. Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011; 14(6):735–743.
14. Au DH, Udris EM, Fihn SD, McDonell MB, Curtis JR. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med. 2006;166(3):326–331.
15. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol. 2015;81(1):161–170.
16. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445.
17. Swedish National Register for Respiratory Failure (Swedevox). Annual Report. 2014. Available from: www.ucr.uu.se/swedevox/. Accessed October 9, 2015.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649–655.
19. Ekström MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720.
20. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735.
21. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2011. WHO; 2010.
22. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388–399.
23. Janssen DJ, de Hosson SM, bij de Vaate E, Mooren KJ, Baas AA. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians. Chron Respir Dis. 2015;12(2):85–92.
24. Ekström M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: a systematic review. Ann Am Thorac Soc. 2015;12(7): 1079–1092.
25. Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009;64(10):910–915.
26. Currow DC, Quinn S, Greene A, Bull J, Johnson MJ, Abernethy AP. The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. J Palliat Med. 2013;16(8):881–886.
27. Rocker GM, Simpson AC, Joanne Young B, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open. 2013;1(1):E27–E36.
28. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J Pain Symptom Manage. 2012;43(3):614–624.
29. Mularski RA, Campbell ML, Asch SM, et al. A review of quality of care evaluation for the palliation of dyspnea. Am J Respir Crit Care Med. 2010;181(6):534–538.
30. Ekström M, Bornefalk-Hermansson A, Abernethy A, Currow D. Lowdose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). Evid Based Med. 2015;20(1):39.
31. Ekström MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. BMJ. 2015;349:g7617.